FDA Clearance Tracker · P030052-S012
UROVYSION BLADDER CANCER KIT
Last checked: Nov 20, 2026Latest source record: Jan 24, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Jan 24, 2014
Approved
Time to decision
148 days
Received Aug 29, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P030052-S012
- Device name
- UROVYSION BLADDER CANCER KIT
- Applicant
- Abbott Molecular
- Applicant location
- Des Plaines, IL
- Received
- Aug 29, 2013
- Decided
- Jan 24, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P030052
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A MANUFACTURING SITE LOCATED AT LEICA BIOSYSTEMS IN SOLON MILLS, ILLINOIS.
Source documents
Other decisions for Abbott Molecular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
- Alinity m HR HPVPMA supplement
P230003-S006 · Decided Sep 10, 2025 · 264 days after receipt · Panel Track
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
K243489 · Decided Jul 28, 2025 · 258 days after receipt
Device type: Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.